Haystack Mrd™ By Quest Diagnostics®

Haystack Mrd™ By Quest Diagnostics® company information, Employees & Contact Information

Haystack MRD™ by Quest Diagnostics is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after cancer treatment. Based on more than 20 years of clinical development and technology from pioneers in cancer genomics at Johns Hopkins University, Haystack MRD's purpose-built, high-precision science delivers novel insights that can help inform treatment decision-making.

Company Details

Employees
54
Founded
-
Address
301 W 29th St, Suite 2004u,germany
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
3.
HQ
Baltimore, Maryland
Looking for a particular Haystack Mrd™ By Quest Diagnostics® employee's phone or email?

Haystack Mrd™ By Quest Diagnostics® Questions

News

MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics® - PR Newswire

MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics® PR Newswire

FDA Grants Breakthrough Device Designation to Haystack MRD ctDNA Liquid Biopsy for Stage II CRC - OncLive

FDA Grants Breakthrough Device Designation to Haystack MRD ctDNA Liquid Biopsy for Stage II CRC OncLive

FDA Fast-Tracks Revolutionary Blood Test: Quest Diagnostics' Breakthrough Could Transform Colorectal Cancer Care - Stock Titan

FDA Fast-Tracks Revolutionary Blood Test: Quest Diagnostics' Breakthrough Could Transform Colorectal Cancer Care Stock Titan

Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types - PR Newswire

Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types PR Newswire

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer - WV News

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer WV News

Major Clinical Trials Launch: New Blood Test Could Transform Post-Surgery Cancer Detection - Stock Titan

Major Clinical Trials Launch: New Blood Test Could Transform Post-Surgery Cancer Detection Stock Titan

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics - PR Newswire

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics PR Newswire

Haystack MRD Test Earns FDA Breakthrough Device Designation in Stage II CRC - CancerNetwork

Haystack MRD Test Earns FDA Breakthrough Device Designation in Stage II CRC CancerNetwork

Haystack MRD Test Gets Breakthrough Designation in Stage 2 Colorectal Cancer - CUREtoday.com

Haystack MRD Test Gets Breakthrough Designation in Stage 2 Colorectal Cancer CUREtoday.com

Haystack MRD by Quest Diagnostics Received FDA Breakthrough Device Designation - Oncodaily

Haystack MRD by Quest Diagnostics Received FDA Breakthrough Device Designation Oncodaily

Lisata to use Haystack’s MRD tests for pancreatic cancer therapy trial - Clinical Trials Arena

Lisata to use Haystack’s MRD tests for pancreatic cancer therapy trial Clinical Trials Arena

Breakthrough Cancer Detection: Quest's Haystack and Rutgers Test DNA-Guided Lung Cancer Treatment - Stock Titan

Breakthrough Cancer Detection: Quest's Haystack and Rutgers Test DNA-Guided Lung Cancer Treatment Stock Titan

Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds - PR Newswire

Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds PR Newswire

Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum - PR Newswire

Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum PR Newswire

Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer - PR Newswire

Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer PR Newswire

Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC - PR Newswire

Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC PR Newswire

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant